All Stories

  1. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
  2. CTEPH is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies
  3. Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease
  4. Long COVID and cardiovascular disease: a prospective cohort study
  5. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
  6. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
  7. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  8. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis
  9. Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  10. Accelerated immune ageing is associated with COVID-19 disease severity
  11. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial
  12. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
  13. Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury
  14. Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis
  15. Long COVID research: an update from the PHOSP-COVID Scientific Summit
  16. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
  17. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  18. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  19. Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease
  20. Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis
  21. Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts
  22. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
  23. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
  24. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  25. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID
  26. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study
  27. Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
  28. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
  29. Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study
  30. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
  31. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
  32. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  33. Los primeros pasos hacia el futuro de la EPID: contribuyendo al conocimiento
  34. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  35. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  36. Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting: An International Delphi Survey
  37. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
  38. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
  39. An update on interstitial lung disease
  40. Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service
  41. Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention
  42. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
  43. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  44. CARTA AL EDITOR SOBRE ARTICULO: Enfermedad pulmonar intersticial difusa asociada a enfermedades autoinmunes
  45. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity
  46. Dexamethasone in Hospitalized Patients with Covid-19
  47. Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?
  48. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  49. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study
  50. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
  51. Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers
  52. Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD
  53. How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians
  54. Predictive variables to obtain a bronchoalveolar lavage of adequate quality in patients with interstitial lung diseases
  55. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group
  56. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study
  57. Trabecular bone score in active or former smokers with and without COPD
  58. Interstitial Lung Diseases in Developing Countries
  59. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
  60. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study